Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Net Income

Bottom-line profit after all expenses, interest, and taxes.

Harrow Health, Inc.NASDAQ: HROW

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$27.6M, compared with -$17.78M a year earlier. Trailing-twelve-month net income was -$14.96M.

Context

  • Net income amounted to 1.9% of revenue in FY2025, down 6.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$12.27M (-138.7%) for the fiscal year ending Dec 2026, a slowdown from the +70.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$27.6M-516.6% QoQ
Last fiscal yearDec 2025
-$5.14M+70.6% YoY
LTMMar 2026
-$14.96M+31.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.2%-237.9%-182.7 pp
1 year+70.6%-138.7%-209.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(5.14M) USD
Year-over-year change
+70.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.0% is the 2nd highest of 8, against a peer median of -50.7%.
  • Net income amounts to 5.6% of revenue for HROW, versus a peer median of 2062.4%.
HROW Competitors
Net Income for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.84M USD———
HROWHarrow Health, Inc.LTM Mar 2026-$14.96M USD+31.0%—5.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$60.96M USD-388.6%—18297.5%
OCSOculis Holding AGLTM Mar 2026-CHF 95.06M CHF+7.6%—18861.3%
BLCOBausch + Lomb CorporationLTM Jun 2026-$171M USD+37.4%—3.2%
KODKodiak Sciences Inc.LTM Sep 2026-$246.76M USD-13.5%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$271.6M USD-85.0%—3566.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$290.5M USD-50.7%—558.2%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-$702.23M USD-765.3%—102.9%
Peer median (excluding HROW) —-50.7%—2062.4%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.